Apyx Medical Announces Positive Clinical Data for Renuvion in Cellulite and Skin Laxity Treatment
APYX has more than doubled off its 52-week low of $1.38.
Summary
Apyx Medical announced new clinical data showing its Renuvion system, combined with Avéli, significantly improves cellulite and skin laxity, validating its efficacy for a widespread aesthetic concern.
Key Events · Product Development and Regulatory · APYX
-
New Clinical Study Published
Apyx Medical announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum.
-
Renuvion Efficacy for Cellulite and Skin Laxity
The study highlighted a promising approach using Renuvion and Avéli, showing up to 81.8% patient improvement in cellulite appearance and objective reductions in dimple volume.
-
Tissue Remodeling Observed
Histological analysis demonstrated increased collagen and elastin, with improved dermal architecture and progressive tissue remodeling through 180 days post-treatment.
Analysis · APYX · Industrial Applications And Services
This 8-K announces the publication of a new clinical study demonstrating significant improvements in cellulite and skin laxity using Apyx Medical's Renuvion system in combination with Avéli. The study showed up to 81.8% of patients improved, with objective reductions in dimple volume and increased collagen/elastin. This positive clinical validation strengthens the market position and potential adoption of Renuvion for common aesthetic concerns.
At the time of this filing, APYX was trading at $4.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $178M. The 52-week trading range was $1.38 to $4.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.